Written and edited by Abel B. Daartey, PharmD

Key Takeaways

• GLP-1 drugs may lower cancer risk indirectly by helping some people lose substantial weight and improve metabolic health.
• The evidence for cancer is promising, but much of it is observational, so it cannot yet prove that GLP-1 medicines prevent cancer.
• These medicines should be used under medical supervision, especially given that thyroid-, gallbladder-, pancreas-, kidney-, and eye-related safety concerns still matter.

GLP-1 medicines have moved very quickly from diabetes clinics into the center of public conversation. Many people know them by brand names such as Ozempic, Wegovy, Mounjaro, and Zepbound. At first, the main story was blood sugar. Then it became weight loss. Now, a more complicated question is emerging: could these drugs also change cancer risk?

The short answer is this: maybe, for some cancers, in some people. But that is not the same as saying these medicines are cancer-prevention drugs.

The reason scientists are paying attention is simple. Excess body fat is not just stored energy sitting quietly under the skin. It is biologically active tissue. It can influence insulin signaling, chronic inflammation, sex hormone metabolism, adipokines, immune surveillance, and cellular growth pathways. These are exactly the types of biological systems that can shape cancer risk over time.

So when a medication class produces large, sustained weight loss, scientists naturally ask whether cancer risk may also shift. That is the scientific story behind the GLP-1 and cancer debate.

What GLP-1 Drugs Actually Do

GLP-1 stands for glucagon-like peptide-1. It is a gut hormone involved in glucose regulation, appetite regulation, gastric emptying, and communication among the gut, pancreas, and brain. GLP-1 receptor agonists mimic this hormone. They help the pancreas release insulin when glucose is high, reduce glucagon signaling, slow gastric emptying, and increase satiety.

In plain language, many people feel full earlier, eat less, and lose weight. The magnitude of that weight loss is one reason this field changed so fast.

In the STEP 1 trial, once-weekly semaglutide 2.4 mg resulted in a mean body weight reduction of 14.9% after 68 weeks, compared with 2.4% in the placebo group ^[1]. In the SURMOUNT-1 trial, tirzepatide produced mean weight reductions from 15.0% to 20.9% after 72 weeks, compared with 3.1% with placebo ^[2].

Those numbers matter because weight loss of that scale is not cosmetic biology. It can alter insulin resistance, inflammatory tone, liver fat, blood pressure, lipid patterns, and other disease-driving systems.

Why Obesity Is Connected to Cancer

The cancer link begins with obesity itself. In 2016, an International Agency for Research on Cancer working group reviewed the evidence and concluded that excess body fat is associated with increased risk for multiple cancers, including colorectal, liver, gallbladder, pancreatic, kidney, esophageal adenocarcinoma, endometrial, ovarian, postmenopausal breast cancer, thyroid cancer, multiple myeloma, gastric cardia cancer, and meningioma ^[3].

That does not mean every person with obesity will develop cancer. It means that at the population level, excess adiposity shifts the biological environment in ways that can increase the likelihood of cancer.

One major pathway is insulin resistance. When tissues become resistant to insulin, the body often compensates by producing more insulin. Insulin and insulin-like growth factor signaling can support cell growth and survival. Another pathway is chronic low-grade inflammation. Adipose tissue can release inflammatory mediators that maintain immune and stromal cell activation. Over years, that kind of environment may support DNA damage, abnormal cell survival, and tumor promotion.

Sex hormones also matter, especially in endometrial and postmenopausal breast cancer. Adipose tissue contributes to estrogen production, and higher estrogen exposure can stimulate hormone-sensitive tissues. This is one reason weight, metabolism, and cancer cannot be discussed as separate topics.

So, Do GLP-1 Drugs Reduce Cancer Risk?

The most honest answer is that the early human data are interesting but not definitive.

A 2024 study in JAMA Network Open examined more than 1.6 million patients with type 2 diabetes and no prior diagnosis of 13 obesity-associated cancers. Compared with insulin, use of GLP-1 receptor agonists was associated with a lower risk of 10 of the 13 obesity-associated cancers studied, including colorectal, liver, pancreatic, ovarian, endometrial, kidney, gallbladder, esophageal, multiple myeloma, and meningioma ^[4].

That sounds powerful, but the comparison matters. Insulin users often have more advanced diabetes, longer disease duration, or different metabolic risk profiles. The authors used statistical methods to adjust for measured differences, but observational studies cannot fully control for unmeasured confounding.

When GLP-1 drugs were compared with metformin in the same study, the cancer signal was less convincing. GLP-1 use was not associated with lower risk of any cancer compared with metformin, and kidney cancer risk was higher in that comparison ^[4]. This is one of the reasons the evidence should be interpreted carefully.

A separate 2025 nationwide cohort study in JNCI: Journal of the National Cancer Institute studied 919,609 overweight or obese patients with type 2 diabetes. GLP-1 agonist use was associated with a lower incidence of obesity-related cancer compared with other glucose-lowering drugs overall, with an adjusted hazard ratio of 0.87 ^[5]. The association appeared stronger as body weight increased.

That finding supports the idea that GLP-1 therapy may matter most in the metabolic conditions where obesity-related cancer risk is already elevated. But again, this was not a randomized cancer-prevention trial.

What About People Who Already Have Cancer?

This question is even newer.

A 2026 cohort study in JAMA Network Open examined patients with breast cancer and obesity-related metabolic conditions. Use of GLP-1 receptor agonists was associated with improved survival and recurrence-free outcomes ^[6]. That is an important signal, but it should not be overread. People who receive GLP-1 drugs may differ from those who do not in many ways, including health care access, metabolic control, body weight, comorbidities, and treatment patterns.

The right interpretation is not “GLP-1 drugs treat breast cancer.” The right interpretation is that metabolic therapy may influence the terrain in which some cancers behave, and randomized trials are needed to test whether that signal is real.

The Biology Is Plausible, But Complicated

The most plausible cancer benefit from GLP-1 drugs is indirect. If a drug reduces body fat, improves insulin sensitivity, lowers chronic inflammation, improves fatty liver disease, and reduces cardiometabolic stress, then cancer risk could reasonably fall over time.

There may also be direct effects. Some preclinical studies suggest that GLP-1 signaling can influence inflammatory pathways, immune metabolism, cellular stress responses, and tissue repair. But the direction may not be identical across all organs. A pathway that is protective in one tissue may raise theoretical concern in another.

A 2026 review in Nature Reviews Clinical Oncology described the evidence as heterogeneous. The authors noted possible lower risk for some cancers, including hepatocellular, esophageal, endometrial, ovarian, and prostate cancers, while also emphasizing continuing concerns around thyroid cancer signals and the limitations of current observational evidence ^[7].

Another Nature Reviews Cancer commentary made a useful point: GLP-1 drugs should not be treated as a magic bullet. Weight loss without attention to nutrition, resistance exercise, and muscle preservation may create new problems, especially in people already vulnerable to frailty or cancer-related muscle loss ^[8].

The Pancreas Question

The pancreas has been one of the most sensitive parts of this debate. GLP-1 drugs act partly through pancreatic biology, so early concerns about pancreatitis and pancreatic cancer were taken seriously.

A 2024 JAMA Network Open cohort study did not find support for increased pancreatic cancer risk among GLP-1 receptor agonist users with type 2 diabetes during follow-up ^[9]. A 2026 review in npj Gut and Liver reached a cautious conclusion: most clinical studies to date do not show a significant association between GLP-1 receptor agonists and pancreatic ductal adenocarcinoma, but long-term data remain limited ^[10].

That is the key balance. The current human evidence does not confirm the early pancreatic cancer fear, but the drugs are still relatively young at population scale. Long-term surveillance remains necessary.

The Thyroid Warning Still Matters

Semaglutide products carry a boxed warning about thyroid C-cell tumors based on rodent findings. The human relevance remains uncertain, but the warning is not trivial. These medicines are contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 ^{[11], [12]}.

There are also warnings around pancreatitis, gallbladder disease, kidney injury related to dehydration or volume depletion, hypoglycemia when combined with insulin or insulin secretagogues, diabetic retinopathy complications in some patients, severe gastrointestinal reactions, and aspiration risk during procedures because gastric emptying may be delayed ^{[11], [12]}.

That does not mean the drugs are unsafe for everyone. It means they are real pharmacological agents, not casual wellness injections.

The Cardiovascular Evidence Is Stronger Than the Cancer Evidence

One reason people are taking the GLP-1 story seriously is that the benefits are not limited to weight. In the SELECT trial, semaglutide reduced major adverse cardiovascular events in adults with established cardiovascular disease and overweight or obesity, even without diabetes ^[13]. The FDA later approved Wegovy to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and either obesity or overweight ^[14].

This matters because it shows that GLP-1 drugs can change hard clinical outcomes, not just scale numbers. But cancer is different. Cancer often develops over many years. To prove prevention, researchers need long follow-up periods, careful control groups, and sufficient numbers of cancer events to make the result reliable.

The Bottom Line

The most responsible conclusion is this: GLP-1 drugs may reduce the risk of some obesity-related cancers, mostly through weight loss and improved metabolic health. The human data are promising enough to justify serious research, but not strong enough to call these drugs cancer-prevention therapy.

For people with obesity, type 2 diabetes, or high cardiovascular risk, GLP-1 medicines may offer meaningful benefits when prescribed appropriately. For cancer prevention specifically, the evidence is still developing.

So the better question is not, “Do these drugs prevent cancer?” The better question is, “What happens to cancer risk when we successfully treat the metabolic environment that helps some cancers grow?”

That question is where the science is heading.

Medical note: This article is for informational purposes only and does not constitute medical advice. GLP-1 medicines should be used only under the guidance of a qualified health care professional.

References

1. J. P. H. Wilding, R. L. Batterham, S. Calanna, et al., “Once-weekly semaglutide in adults with overweight or obesity,” N Engl J Med, vol. 384, pp. 989-1002, 2021. doi: 10.1056/NEJMoa2032183
2. A. M. Jastreboff, L. J. Aronne, N. N. Ahmad, et al., “Tirzepatide once weekly for the treatment of obesity,” N Engl J Med, vol. 387, pp. 205-216, 2022. doi: 10.1056/NEJMoa2206038
3. B. Lauby-Secretan, C. Scoccianti, D. Loomis, et al., “Body fatness and cancer: viewpoint of the IARC Working Group,” N Engl J Med, vol. 375, pp. 794-798, 2016. doi: 10.1056/NEJMsr1606602
4. L. Wang, R. Xu, D. C. Kaelber, and N. A. Berger, “Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes,” JAMA Netw Open, vol. 7, no. 7, e2421305, 2024. doi: 10.1001/jamanetworkopen.2024.21305
5. X. Mao, X. Zhang, L. Henry, et al., “Association between glucagon-like peptidase 1 receptor agonist and obesity-related cancer in overweight or obese patients with type 2 diabetes: a nationwide cohort study,” JNCI J Natl Cancer Inst, vol. 117, no. 10, pp. 2053-2061, 2025. doi: 10.1093/jnci/djaf163
6. K. L. Tatum, B. Dahman, A. Stevenson, et al., “Survival and recurrence with GLP-1 receptor agonists in breast cancer,” JAMA Netw Open, vol. 9, no. 5, e2612133, 2026. doi: 10.1001/jamanetworkopen.2026.12133
7. E. Mannucci and I. Dicembrini, “Glucagon-like peptide 1 receptor agonists and cancer risk: the good, the bad and the unknown,” Nat Rev Clin Oncol, vol. 23, pp. 459-470, 2026. doi: 10.1038/s41571-026-01135-0
8. J. R. Hebert, E. A. Murphy, M. C. Playdon, et al., “Are GLP-1 receptor agonists a ‘magic bullet’ for cancer?” Nat Rev Cancer, vol. 26, pp. 3-4, 2026. doi: 10.1038/s41568-025-00874-z
9. R. Dankner, H. Murad, N. Agay, et al., “Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk in patients with type 2 diabetes,” JAMA Netw Open, vol. 7, no. 1, e2350408, 2024. doi: 10.1001/jamanetworkopen.2023.50408
10. S. Krishna, K. M. Dungan, R. Shah, et al., “Risk of pancreatic cancer associated with GLP-1 receptor agonist therapy,” npj Gut Liver, vol. 3, article 24, 2026. doi: 10.1038/s44355-026-00069-9
11. DailyMed, “Ozempic (semaglutide) injection, prescribing information,” revised May 2026. Available: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
12. DailyMed, “Wegovy (semaglutide) injection, prescribing information.” Available: https://dailymed.nlm.nih.gov
13. A. M. Lincoff, K. Brown-Frandsen, H. M. Colhoun, et al., “Semaglutide and cardiovascular outcomes in obesity without diabetes,” N Engl J Med, vol. 389, pp. 2221-2232, 2023. doi: 10.1056/NEJMoa2307563
14. U.S. Food and Drug Administration, “FDA approves first treatment to reduce risk of serious heart problems specifically in adults with obesity or overweight,” Mar. 8, 2024. Available: https://www.fda.gov